About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.
About 1 in 5000 males are born with hemophilia, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program
Transcript
What are some current trends in hemophilia incidence?
Hemophilia is a congenital disorder. It's a defective gene for factor VIII, which is hemophilia A or defective gene for factor VIIII, which is hemophilia B. The incidence of hemophilia A and B has been quite static for decades, and it's probably because we've improved the health of carriers as well as the population itself. So, we really don't see any significant changes going forward from what we've been used to seeing over the last few years. There's 30,000-33,000 patients with hemophilia in the US, about 85% of those have hemophilia A, so a factor VIII deficiency; the others are hemophilia B. Just to give you some perspective, it's about 1 in 5000 male births affected by hemophilia. And of those, almost 50% of them are going to have the severe form of the condition.
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More